Combination drug treatment benefits patients with HIVBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7053.320 (Published 10 August 1996) Cite this as: BMJ 1996;313:320
The long awaited Delta study has confirmed that treating patients infected with HIV with a combination of zidovudine (AZT) plus either didanosine (ddI) or zalcitabine (ddC) prolongs life and delays disease progression compared with treatment with zidovudine alone. Even patients who had already treated with zidovudine found some additional benefit when didanosine was added, although the effect was less pronounced.
The international randomised double blind trial had more than 3000 participants, …
Log in using your username and password
Log in through your institution
Sign up for a free trial